PFE - Valneva Pfizer delay end date of Lyme disease vaccine phase 3 trial to 2025
2023-03-24 13:36:06 ET
- Valneva ( NASDAQ: VALN ) and Pfizer ( NYSE: PFE ) have pushed back by a year the end date of a phase 3 trial for their Lyme disease vaccine candidate VLA15.
- The new estimated completion date for the VALOR trial is December 2025, according to clinicaltrials.gov .
- Valneva is down ~10% in Friday afternoon trading.
- The delay is because a significant number of participants had to be discontinued from the trial at sites run by a third-party contractor due to violations of Good Clinical Practices .
- In its Q4 2022 financial results posted earlier Friday, Valneva said that despite the setbacks, Pfizer ( PFE ) is still aiming to file an application for the vaccine by its original deadline, 2025.
- Read why Seeking Alpha contributor BiotechValley Insights rates Valneva ( OTCPK:INRLF ) a buy.
For further details see:
Valneva, Pfizer delay end date of Lyme disease vaccine phase 3 trial to 2025